Lonza Will Purchase a Sterile Fill-Finish Site from Novartis

Facility will be the first fill-finish site for Lonza.

To build on existing parenteral drug product development and testing capabilities, Lonza Pharma & Biotech has agreed to purchase a fill-finish facility in Stein, Switzerland from Novartis. With the addition of this site to its network, Lonza will be able to offer end-to-end services for clinical supply and commercial launch of parenteral drug products.

 

The financial terms of the deal were not disclosed, but it is expected to be finalized within a few months. Lonza will continue to produce products for Novartis, as well as take on contract manufacturing projects for other customers. The facility, which currently serves as the Novartis Center of Excellence for sterile clinical (phases I to III) drug product manufacturing, is designed for multi-product production.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.